Indian Journal of Nuclear Medicine

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 35  |  Issue : 4  |  Page : 299--304

Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer


Swayamjeet Satapathy1, Bhagwant Rai Mittal1, Ashwani Sood1, Chandan Krushna Das2, Shrawan Kumar Singh3, Ravimohan Suryanarayan Mavuduru3, Girdhar Singh Bora3 
1 Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Medical Oncology, Regional Cancer Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Dr. Ashwani Sood
Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh - 160 012
India

Aims: Actinium-225 (225Ac) labeled prostate-specific membrane antigen (PSMA)-617 is a novel treatment modality in the management of metastatic castration-resistant prostate cancer (mCRPC). The present study was conducted to assess the impact of 225Ac-PSMA-617 therapy on the quality-of-life of patients with heavily pretreated mCRPC using the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Prostate Symptom Index-17 (NCCN-FACT-FPSI-17) questionnaire. Materials and Methods: This was a retrospective single-center study where data of consecutive heavily pretreated mCRPC patients treated with 225Ac-PSMA-617 from January 2019 to February 2020, was collected and analyzed for the biochemical response, quality-of-life outcomes and treatment-related toxicity. Results: Eleven heavily pretreated mCRPC patients received a median cumulative dose of 8.3 MBq (interquartile range [IQR] 5.6–20.4 MBq) 225Ac-PSMA-617 over 1–4 cycles. 5/11 patients (46%) showed a ≥50% decline in Prostate Specific Antigen (PSA), while stable values and PSA progression were observed in 3/11 (27%) patients each. Pre- and post-therapy NCCN-FACT-FPSI-17 questionnaires revealed statistically significant improvement in the total FPSI score (P = 0.003) as well as the disease-related symptoms-physical (P = 0.004) and disease-related symptoms-emotional (P = 0.046) subscores. Among the physical symptoms, significant improvement was noted with respect to pain, difficulty in urination, bone pain, fatigue, and restriction in physical activity. No significant change was noted in the treatment side-effects subscore. Of the treatment-related adverse effects, Grade 3 dryness of the mouth, anemia, and nephrotoxicity was observed in 1/11 patients (9%) each and Grade 3 thrombocytopenia in 2/11 patients (18%). Conclusion: Health-related quality-of-life of the mCRPC patients improved significantly with225Ac-PSMA-617 despite extensive pretreatment and advanced nature of the disease.


How to cite this article:
Satapathy S, Mittal BR, Sood A, Das CK, Singh SK, Mavuduru RS, Bora GS. Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer.Indian J Nucl Med 2020;35:299-304


How to cite this URL:
Satapathy S, Mittal BR, Sood A, Das CK, Singh SK, Mavuduru RS, Bora GS. Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. Indian J Nucl Med [serial online] 2020 [cited 2021 Apr 18 ];35:299-304
Available from: https://www.ijnm.in/article.asp?issn=0972-3919;year=2020;volume=35;issue=4;spage=299;epage=304;aulast=Satapathy;type=0